Bayer Grants4Apps® Dealmaker Berlin 2017

Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

Grants4Apps team has put together specific challenges, applicants are asked to address one or multiple of these challenges below. However, the team is also open for other solutions that help healthcare providers or patients, as well as products dedicated to preventing or diagnosing diseases or improving pharmaceutical processes.

The Challenges

Hemophilia

  • Empower hemophilia (bleeding disease) patients to individually adjust their treatment regimen to lead active lives.

Women's Health

  • Enabling earlier diagnosis of endometriosis.
  • Enhancing intrauterine device insertion training for providers.
  • Providing effective contraceptive counseling (face to face, remote or automated).
  • Improving comfort and experience during intrauterine device insertion for both providers & patients.
  • Simplifying the thread/placement check post-insertion of intrauterine devices.

Pulmonology

  • Improve identification of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) patients.
  • Improve adherence for an oral pulmonary hypertension treatment.
  • Innovative and efficient concepts for training staff to use a drug and device combination product in an intensive care unit setting.
  • Create awareness for limited outcome of standard of care treatment for pneumonia in the hospital.

Ophthalmology

  • Remote/mobile screening for Diabetic Retinopathy.
  • Remote monitoring of patients treated with anti-Vascular Endothelial Growth Factors (VEGFs).
  • Utilizing real-world evidence (RWE) to predict the need for anti-Vascular Endothelial Growth Factors (VEGFs)-injections.

Nephrology

  • Monitoring of chronic kidney disease (CKD).
  • Diagnosis of acute kidney injury.

Artificial Intelligence

  • Prediction of combination therapies for cancer.
  • Extract compound structures and Structure-Activity Relationship (SAR) data from patents.
  • Computer-assisted identification of new compounds for protein targets.
  • Develop analysis tool for in vivo experiments.

Data Analytics

  • Data analysis tools to systematically identify worldwide activities in Research & Development.
  • Deep Learning Research Services for health and life science data.
  • Transforming Electronic Health Records (EHR) data to analysis data sets.
  • Analyze drug labels to generate new insights.
  • Develop efficient analysis of large scientific literature corpi to generate insights.
  • How to implement prediction algorithms in hospital information systems.
  • Social Media use in pharma.

Clinical Trials

  • Patient identification and recruitment for clinical trials.
  • Improving the patient experience in clinical trials.
  • Develop a mobile platform for patients to report their health condition parameters.
  • Adherence improvement in (clinical trials OR) real life.

Submission deadline: 30 June 2017

For further information, please visit:
https://www.grants4apps.com/berlin/program/dealmaker-berlin-2017/

About Grants4Apps®
We connect health startups with industry experts and help the best talents to thrive within the digital healthcare universe. We are looking for startups beyond the ideation phase developing health technology or IT solutions that can connect and empower patients or healthcare stakeholders.

There are no boundaries to creativity!

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...